Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD
Add to favourite- Summary
- Historical Data
| Spread | 17.1 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.011661% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.010562% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | JPY | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Japan | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6598.2 |
| Open | 6515.6 |
| 1-Year Change | 10.11% |
| Day's Range | 6488.5 - 6619.5 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 6619.5 | 66.0 | 1.01% | 6553.5 | 6620.5 | 6488.5 |
| Jan 16, 2025 | 6598.2 | -165.1 | -2.44% | 6763.3 | 6775.3 | 6598.2 |
| Jan 15, 2025 | 6702.2 | -125.0 | -1.83% | 6827.2 | 6869.2 | 6597.3 |
| Jan 14, 2025 | 6774.3 | 35.0 | 0.52% | 6739.3 | 6908.1 | 6739.3 |
| Jan 10, 2025 | 6727.3 | -135.0 | -1.97% | 6862.3 | 6862.3 | 6569.6 |
| Jan 9, 2025 | 6942.2 | 148.0 | 2.18% | 6794.2 | 6945.0 | 6785.3 |
| Jan 8, 2025 | 6722.3 | -103.5 | -1.52% | 6825.8 | 6826.2 | 6689.4 |
| Jan 7, 2025 | 6833.2 | 10.0 | 0.15% | 6823.2 | 6867.6 | 6777.3 |
| Jan 6, 2025 | 6818.2 | -155.9 | -2.24% | 6974.1 | 6992.0 | 6756.3 |
| Dec 30, 2024 | 6967.1 | -137.8 | -1.94% | 7104.9 | 7106.9 | 6962.1 |
| Dec 27, 2024 | 7091.9 | 125.6 | 1.80% | 6966.3 | 7147.2 | 6966.3 |
| Dec 26, 2024 | 6905.1 | -11.1 | -0.16% | 6916.2 | 6961.1 | 6897.1 |
| Dec 24, 2024 | 6905.1 | 18.1 | 0.26% | 6887.0 | 6967.2 | 6871.2 |
| Dec 23, 2024 | 6903.1 | 95.9 | 1.41% | 6807.2 | 6923.6 | 6764.3 |
| Dec 20, 2024 | 6698.5 | -89.8 | -1.32% | 6788.3 | 6815.5 | 6689.5 |
| Dec 19, 2024 | 6686.7 | -3.6 | -0.05% | 6690.3 | 6777.4 | 6658.7 |
| Dec 18, 2024 | 6817.2 | -128.9 | -1.86% | 6946.1 | 6951.1 | 6787.6 |
| Dec 17, 2024 | 6992.0 | 150.8 | 2.20% | 6841.2 | 7016.0 | 6835.3 |
| Dec 16, 2024 | 6739.3 | 131.9 | 2.00% | 6607.4 | 6758.3 | 6567.7 |
| Dec 13, 2024 | 6601.4 | -95.9 | -1.43% | 6697.3 | 6755.3 | 6578.4 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Chugai Pharmaceutical Co., Ltd. Company profile
About Chugai Pharmaceutical Co Ltd
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chugai Pharmaceutical Co Ltd revenues increased 27% to Y999.76B. Net income increased 41% to Y303B. Revenues reflect Net Sales increase of 27% to Y802.84B, Royalties and other operating revenues increase of 28% to Y196.92B. Dividend per share increased from Y55.00 to Y76.00. Basic Earnings per Share excluding Extraordinary Items increased from Y130.66 to Y184.29.
Equity composition
FY'03, the Co. changed FY end from March to December. FY'94-'02 WAS & FY'04 Q1 &Q3 WAs & O/S were estimated. 3/05 & 9/05, WAS, O/S, DPS were estimated. FY'06 Q3 & '07 Q1, Q3 WAS& DWAS were estimated, and its WAS was used as O/S. FY'08 1Q WAS & DWAS were estimated and WAS was used as o/s. FY'08 Q3 WAS estimated and used as o/s.
| Industry: | Pharmaceuticals (NEC) |
日本橋三井タワー15f
日本橋室町2-1-1
CHUO-KU
TOKYO-TO 103-8324
JP
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com